Filing Details

Accession Number:
0001019687-15-004483
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-11 16:05:53
Reporting Period:
2015-10-27
Filing Date:
2015-12-11
Accepted Time:
2015-12-11 16:05:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1374536 Medytox Solutions Inc. MMMS Services-Testing Laboratories (8734) 900902741
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578723 Eric Christopher Diamantis 400 S. Australian Avenue, 8Th Floor
West Palm Beach FL 33401
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-27 100,000 $1.00 850,000 No 4 P Direct
Common Stock Disposition 2015-11-02 850,000 $0.00 0 No 4 D Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 D Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Options to Purchase Common Stock Acquisiton 2015-11-02 100,000 $0.00 100,000 $5.00
Common Stock Options to Purchase Common Stock Acquisiton 2015-11-02 50,000 $0.00 50,000 $5.00
Common Stock Options to Purchase Common Stock Acquisiton 2015-11-02 100,000 $0.00 100,000 $2.50
Common Stock Options to Purchase Common Stock Acquisiton 2015-11-02 50,000 $0.00 50,000 $2.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2013-04-19 2017-04-19 No 4 D Direct
0 2014-04-19 2017-04-19 No 4 D Direct
0 2013-04-19 2017-04-19 No 4 D Direct
0 2014-04-19 2017-04-19 No 4 D Direct
Footnotes
  1. Disposed of pursuant to merger agreement among Medytox Solutions, Inc. ("Medytox"), CollabRx Merger Sub, Inc. ("Merger Sub"), and Rennova Health, Inc. ("Rennova") (f/k/a/ CollabRx, Inc.) in exchange for 348,193 shares of Rennova common stock.
  2. Cancelled pursuant to merger agreement and related transactions between Medytox and Rennova.
  3. Disposed of pursuant to the merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 40,963 shares of Rennova common stock at an exercise price of $6.11 per share.
  4. Disposed of pursuant to the merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 20,481 shares of Rennova common stock at an exercise price of $6.11 per share.